EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

NF ‐ κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma

Yuto Takahashi, Akihiro Kitadate iD, Sayaka Iwama, Wataru Kuroki, Ko Abe, Masahiro Yamada, Sho Ikeda iD, Hiroyuki Tagawa, Hideki Wakui, Masaki Hikida, Naoto Takahashi iD

Cancer Science · 2026

DOI: 10.1111/cas.70251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Yuto Takahashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Graduate School of Engineering Science, Akita University, Akita, Japan. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Histone Deacetylase Inhibitors, Drug Resistance, Neoplasm, NF-kappa B. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylase inhibitors, such as vorinostat, show promise as treatment for T‐cell lymphomas including cutaneous T‐cell lymphoma. However, the emergence of resistance ultimately leads to disease relapse. To elucidate the underlying mechanisms and identify potential countermeasures, we established histone deacetylase inhibitor‐resistant cutaneous T‐cell lymphoma cell lines by prolonged exposure to vorinostat. We then comprehensively profiled gene expression in these cell lines by using microarrays and in silico analytical approaches. We identified 83 genes that were significantly upregulated in the resistant cell lines. Subsequent enrichment analyses using ChIP‐Atlas and Enrichr revealed that these genes are regulated by particular transcription factors, including RELA/p65, GATA3, and EP300, of which RELA (p65) exhibited the highest composite score. RELA is a key subunit of the NF‐κB complex, which is involved in inflammation, cell survival, and proliferation. We demonstrated marked upregulation and nuclear enrichment of p65 and pronounced NF‐κB pathway activation in the histone deacetylase inhibitor‐resistant cells. The mechanism involved acetylation‐mediated inhibition of p65 ubiquitination, which resulted in protein stabilization and enhanced transcriptional activity. Histone deacetylase inhibitor‐resistant cell lines displayed heightened sensitivity to inhibition of the NF‐κB pathway by bortezomib and dimethyl fumarate. These findings implicate aberrant NF‐κB activation as a central driver of the emergence of histone deacetylase inhibitor resistance in cutaneous T‐cell lymphoma. Ultimately, our results provide a strong rationale for exploring NF‐κB inhibition as a therapeutic strategy to restore or enhance the efficacy of histone deacetylase inhibitor‐based therapies, overcome histone deacetylase inhibitor resistance, and improve outcomes for patients with cutaneous T‐cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousHistone Deacetylase InhibitorsDrug Resistance, NeoplasmNF-kappa BSkin NeoplasmsHumansCell Line, TumorVorinostatGene Expression Regulation, NeoplasticTranscription Factor RelAHydroxamic AcidsSignal TransductionAcetylationE1A-Associated p300 ProteinUbiquitinationGATA3 Transcription Factor

Stichwörter der Autor:innen

NF‐kappa Bcutaneous T‐cell lymphomagene expression profilinghistone deacetylase inhibitorsvorinostat

Substanzen

Histone Deacetylase InhibitorsVorinostatNF-kappa BTranscription Factor RelAHydroxamic AcidsRELA protein, humanGATA3 protein, humanE1A-Associated p300 ProteinEP300 protein, humanGATA3 Transcription Factor

Autor:innen und Institutionen

  • Department of Life Science, Graduate School of Engineering Science, Akita University, Akita, Japan.
  • Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.

ORCID-Profile: Akihiro Kitadate, Sho Ikeda, Naoto Takahashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Takahashi, Y., Kitadate, A., Iwama, S., Kuroki, W., Abe, K., Yamada, M., Ikeda, S., Tagawa, H., Wakui, H., Hikida, M., & Takahashi, N. (2026). NF ‐ κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma. Cancer Science. https://doi.org/10.1111/cas.70251

Vancouver

Takahashi Y, Kitadate A, Iwama S, Kuroki W, Abe K, Yamada M, et al. NF ‐ κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma. Cancer Science. 2026. doi:10.1111/cas.70251

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Yuto and Kitadate, Akihiro and Iwama, Sayaka and Kuroki, Wataru and Abe, Ko and Yamada, Masahiro and Ikeda, Sho and Tagawa, Hiroyuki and Wakui, Hideki and Hikida, Masaki and Takahashi, Naoto},
  title = {NF ‐ κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70251}
}
Kostenlos starten →